Cart
sales@molnova.com
AZD 1678
CAS No. 942137-41-9
AZD 1678( AZD1678 | AZD-1678 )
Catalog No. M16739 CAS No. 942137-41-9
AZD 1678 is a potent, selective orally bioavailable CCR4 receptor antagonist with pIC50 of 8.6 for hCCR4, pIC50 of 9.0 for rCCR4.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAZD 1678
-
NoteResearch use only, not for human use.
-
Brief DescriptionAZD 1678 is a potent, selective orally bioavailable CCR4 receptor antagonist with pIC50 of 8.6 for hCCR4, pIC50 of 9.0 for rCCR4.
-
DescriptionAZD 1678 is a potent, selective orally bioavailable CCR4 receptor antagonist with pIC50 of 8.6 for hCCR4, pIC50 of 9.0 for rCCR4; shows no significant activity against a panel of chemokine receptors (CXCR1, CXCR2, CCR1, CCR2b, CCR5, CCR7, CCR8; inactive at 10 uM); inhibits Th2 cell CCL22 driven chemotaxis in 0.3% HSA with pIC50 of 6.8.Asthma Phase 1 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsAZD1678 | AZD-1678
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research AreaInflammation/Immunology
-
IndicationAsthma
Chemical Information
-
CAS Number942137-41-9
-
Formula Weight352.1614
-
Molecular FormulaC11H8Cl2FN3O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=S(C1=CC=CC(Cl)=C1Cl)(NC2=NC=C(F)N=C2OC)=O
-
Chemical Name2,3-Dichloro-N-(5-fluoro-3-methoxy-2-pyrazinyl)benzenesulfonamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kindon N, et al. ACS Med Chem Lett. 2017 Sep 1;8(9):981-986.
molnova catalog
related products
-
GSK 214096
A potent, selective CCR5 antagonist and HIV-1 entry inhibitor.
-
CMPD167
CMPD167 (MRK-1) is an orally acitve small molecule that binds to CCR5 to inhibit gp120 association.
-
ST 016907
A potent CCR4 antagonist that blocked CCL22- and CCL17-mediated migration of human peripheral blood CD4+CD25+ Treg and Th2 cells ex-vivo and murine Tregs in-vivo.
